Artis Ventures Management, L.P.
Artis TechBio II, L.P.
Late investment period
Late investment period: first sale Apr 2022, per Form D (fund age approximates vintage)
- Vintage
- 2022
- Fund size
- $140.81M to $300M (Form D)
- Stages
- Not stated
- Sectors
- Biotech
- Regions
- Not stated
01 · Thesis
Invests in frontier technologies to make the future of the human condition more resilient, supporting visionary founders reimagining systems that sustain life, with a focus on health, AI, and longevity.Inferred from the firm's website
02 · Initial check
$1.41M to $5M (estimated from fund size)
Estimated from Form D: $140.81M sold of a $300M target
03 · Who to approach
Named on this fund's Form D
- Stuart Peterson, Managing Partner
- Robert Riemer, Executive Officer of Artis Ventures Management IV, LLC, the General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideARTIS invests in frontier technologies to make the future of the human condition more resilient.
ARTIS is guided by a singular belief: that the future of the human condition can be made more resilient through the bold application of frontier technologies.
https://www.av.co/
06 · Sources
Last verified: Oct 28, 2026